Ken Griffin Profound Medical Corp. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.47 - $11.18 $8,964 - $13,416	1,200 New	1,200 $9,000
Q1 2024 May 15, 2024	BUY	$7.3 - $9.46 $730 - $946	100 Added 1.28%	7,900 $67,000
Q4 2023 Feb 14, 2024	SELL	$7.85 - $11.18 $59,660 - $84,968	-7,600 Reduced 49.35%	7,800 $66,000
Q3 2023 Nov 14, 2023	BUY	$7.91 - $13.27 $4,746 - $7,962	600 Added 4.05%	15,400 $157,000
Q1 2023 May 15, 2023	BUY	$8.85 - $13.27 $72,570 - $108,814	8,200 Added 124.24%	14,800 $137,000
Q4 2022 Feb 14, 2023	SELL	$3.18 - $10.91 $154,548 - $530,226	-48,600 Reduced 88.04%	6,600 $71,000
Q3 2022 Nov 14, 2022	BUY	$3.99 - $9.3 $8,379 - $19,530	2,100 Added 3.95%	55,200 $223,000

8.93M

1.2K

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $167M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.